Company: CERO
Filing Date: 2025-10-23
Form Type: 424B3
Source: 0001213900-25-101651
Chunk: 9

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-10-23
Form: 424B3
Chunk 9
---
, and shall not be entitled to call a meeting of such holders for any purpose
nor shall they be entitled to participate in any meeting of the holders of Common Stock, except as provided in the Certificate of Designations
(or as otherwise required by applicable law).

Covenants. The Certificate of Designations
contains a variety of obligations on the Company’s part not to engage in specified activities. In particular, the Company will not,
and will cause the Company’s subsidiaries to not, redeem, repurchase or declare any dividend or distribution on any of the Company’s
capital stock (other than as required under the Certificate of Designations) and will not incur any indebtedness other than ordinary course
trade payables or, subject to certain exceptions, incur any liens. In addition, the Company will not issue any preferred stock or issue
any other securities that would cause a breach or default under the Certificate of Designations.

Reservation Requirements. So long as any
Series E Preferred Stock remains outstanding, the Company shall at all times reserve at least 250% of the number of shares of Common Stock
as shall from time to time be necessary to effect the conversion of all Series E Preferred Stock then outstanding.

Registration Rights Agreement

On the First Closing Date, the Company will enter
into a registration rights agreement by and between the Company and the PIPE Investors (the “Registration Rights Agreement”),
pursuant to which the Company will be required to file a registration statement with the Securities and Exchange Commission (the “SEC”),
to register for resale the Common Stock issuable upon the conversion of the Series E Preferred Stock.

<div align='center'>3</div>

The foregoing description of the Private Placement
does not purport to be complete and is qualified in its entirety by reference to the Certificate of Designations, the Securities Purchase
Agreement, and the Registration Rights Agreement, which are filed as Exhibits 3.1, 10.1, and 10.2 to this Current Report on Form 8-K and
are incorporated by reference herein.

This Current Report on Form 8-K shall not constitute
an offer to sell or a solicitation of an offer to buy, nor shall there be any sale, of the Series E Preferred Stock in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or other jurisdiction.

Item 3.02 Unregistered Sales of Equity Securities.

The information provided in Item 1.